期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 16, 期 12, 页码 3322-3337出版社
WILEY
DOI: 10.1111/ajt.14012
关键词
-
资金
- German Research Foundation (Cluster of Excellence) [EXC306]
- FWO-Vlaanderen
- National Research Agency's (Agence Nationale de Recherche
- ANR)
- Investment for the Future Program's (Programme des Investissements d'Avenir
- PIA) Laboratoire d'Excellence (LabEx) TRANSPLANTEX [ANR-11-LABX-0070_TRANSPLANTEX]
- INSERM [UMR_S 1109]
- ANR
- Franco-Japanese NextGen HLA laboratory
- Ligue contre le Cancer (equipe labelisee)
- Agence National de la Recherche (ANR)-Projets blancs
- ANR under the frame of E-Rare-2
- ERA-Net for Research on Rare Diseases
- Association pour la recherche sur le cancer (ARC)
- Canceropole Ile-de-France
- Institut National du Cancer (INCa)
- Institut Universitaire de France
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- European Research Council (ERC)
- LeDucq Foundation
- LabEx Immuno-Oncology
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- Paris Alliance of Cancer Research Institutes (PACRI)
The pathophysiological importance of the immunogenicity of damage-associated molecular patterns (DAMPs) has been pinpointed by their identification as triggers of allograft rejection following release from dying cells, such as after ischemia-reperfusion injury. In cancers, however, this strong trigger of a specific immune response gives rise to the success of cancer immunotherapy. Here, we review the recently literature on the pathophysiological importance of DAMP release and discuss the implications of these processes for allograft rejection and cancer immunotherapy, revealing a striking mechanistic overlap. We conclude that these two fields share a common mechanistic basis of regulated necrosis and inflammation, the molecular characterization of which may be helpful for both oncologists and the transplant community.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据